Mauna Kea Technologies SA announced a private placement of 11,911,852 common shares at a price of ?0.5037 per share for gross proceeds of ?6,000,000 on November 13, 2023. The transaction included participation from new investor Telix Pharmaceuticals Limited.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.3 AUD | +0.13% | +3.65% | +52.18% |
05-03 | Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP | MT |
04-30 | Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50 | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
15.3 AUD | +0.13% | +3.65% | 3.27B | ||
0.407 EUR | +0.25% | +1.24% | 26.93M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.18% | 3.27B | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Mauna Kea Technologies SA announced that it expects to receive ?6 million in funding from Telix Pharmaceuticals Limited